To explore the clinical significance of ACSL1 and FSP1, and of the ROS biomarkers, 4-HNE and PTGS2, in cancer metastases, tumors samples from patients with ovarian cancer were also tested by immunohistochemistry. Here, AIFM2 is linked to ovarian carcinoma.